Sellas Life Sciences Unveils Phase 2 Data for SLS009 Combo in Relapsed AML at ASH 2025

Reuters11-03

Sellas Life Sciences Unveils Phase 2 Data for SLS009 Combo in Relapsed AML at ASH 2025

Sellas Life Sciences Group Inc. announced that data from its ongoing Phase 2 study of SLS009 will be presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. The trial is evaluating SLS009, a highly selective CDK9 inhibitor, in combination with azacitidine and venetoclax for the treatment of relapsed or refractory acute myeloid leukemia with myelodysplastic syndrome-related changes following prior venetoclax-based treatment. An abstract describing the proposed mechanism of action of SLS009, including its cytotoxic effects in AML cell lines with leukemia-driving mutations, has been published on the ASH Annual Meeting website and will also be available in Blood. The results of the Phase 2 study are to be presented on December 7, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565629-en) on November 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580219357?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580219357","market":"fut","top_or_hot":-1,"title":"Sellas Life Sciences Unveils Phase 2 Data for SLS009 Combo in Relapsed AML at ASH 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sellas Life Sciences Unveils Phase 2 Data for SLS009 Combo in Relapsed AML at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sellas Life Sciences Group Inc. announced that data from its ongoing Phase 2 study of SLS009 will be presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. The trial is evaluating SLS009, a highly selective CDK9 inhibitor, in combination with azacitidine and venetoclax for the treatment of relapsed or refractory acute myeloid leukemia with myelodysplastic syndrome-related changes following prior venetoclax-based treatment. An abstract describing the proposed mechanism of action of SLS009, including its cytotoxic effects in AML cell lines with leukemia-driving mutations, has been published on the ASH Annual Meeting website and will also be available in Blood. The results of the Phase 2 study are to be presented on December 7, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565629-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sellas Life Sciences Unveils Phase 2 Data for SLS009 Combo in Relapsed AML at ASH 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSellas Life Sciences Unveils Phase 2 Data for SLS009 Combo in Relapsed AML at ASH 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sellas Life Sciences Unveils Phase 2 Data for SLS009 Combo in Relapsed AML at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sellas Life Sciences Group Inc. announced that data from its ongoing Phase 2 study of SLS009 will be presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. The trial is evaluating SLS009, a highly selective CDK9 inhibitor, in combination with azacitidine and venetoclax for the treatment of relapsed or refractory acute myeloid leukemia with myelodysplastic syndrome-related changes following prior venetoclax-based treatment. An abstract describing the proposed mechanism of action of SLS009, including its cytotoxic effects in AML cell lines with leukemia-driving mutations, has been published on the ASH Annual Meeting website and will also be available in Blood. The results of the Phase 2 study are to be presented on December 7, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565629-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL5xWz66:1","article_id":"2580219357","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580219357","pubTimestamp":1762178438,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sellas Life Sciences Group Inc. announced that data from its ongoing Phase 2 study of SLS009 will be presented at the 67th American Society of Hematology  Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. The trial is evaluating SLS009, a highly selective CDK9 inhibitor, in combination with azacitidine and venetoclax for the treatment of relapsed or refractory acute myeloid leukemia with myelodysplastic syndrome-related changes following prior venetoclax-based treatment. An abstract describing the proposed mechanism of action of SLS009, including its cytotoxic effects in AML cell lines with leukemia-driving mutations, has been published on the ASH Annual Meeting website and will also be available in Blood. The results of the Phase 2 study are to be presented on December 7, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","SLS":"SELLAS Life Sciences Group Inc.","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Sellas Life Sciences在ASH 2025上公布SLS009组合治疗复发性AML的2期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SLS":0.9},"content_text":"Sellas Life Sciences Unveils Phase 2 Data for SLS009 Combo in Relapsed AML at ASH 2025\n    \n\n        Sellas Life Sciences Group Inc. announced that data from its ongoing Phase 2 study of SLS009 will be presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. The trial is evaluating SLS009, a highly selective CDK9 inhibitor, in combination with azacitidine and venetoclax for the treatment of relapsed or refractory acute myeloid leukemia with myelodysplastic syndrome-related changes following prior venetoclax-based treatment. An abstract describing the proposed mechanism of action of SLS009, including its cytotoxic effects in AML cell lines with leukemia-driving mutations, has been published on the ASH Annual Meeting website and will also be available in Blood. The results of the Phase 2 study are to be presented on December 7, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565629-en) on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580219357","isCrawlerRequest":true}